{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:12:37Z","timestamp":1779167557524,"version":"3.51.4"},"reference-count":35,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Certolizumab pegol (CZP) is an Fc\u2010free, PEGylated anti\u2010tumor necrosis factor biologic.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To report 3\u2010year outcomes from the CIMPACT (NCT02346240) phase 3, CZP in moderate to severe plaque psoriasis, randomized controlled trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adults were randomized 3:3:3:1 to CZP 200\u2009mg every other week (Q2W), CZP 400\u2009mg Q2W, etanercept biweekly or placebo. At Week 16, CZP\u2010 and etanercept\u2010treated PASI 75 responders were re\u2010randomized to CZP 200\u2009mg Q2W, CZP 400\u2009mg Q4W, CZP\u2009400\u2009mg Q2W or placebo for maintenance treatment; PASI 75 non\u2010responders entered an open\u2010label escape CZP 400\u2009mg Q2W arm. Patients entering the open\u2010label extension (OLE; Weeks 48\u2013144) from blinded treatment received CZP\u2009200\u2009mg Q2W.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Double\u2010blinded results have been reported previously. 261 patients received 200\u2009mg Q2W upon OLE entry. PASI 75 response was maintained in patients continuing 200\u2009mg Q2W treatment through Weeks 16\u2013144 (Week\u2009144: 96.2%). In patients dosed down at Week 48 (double\u2010blinded 400 mg to 200\u2009mg Q2W), PASI 75 decreased (Week\u200948:\u200998.7%; Week 144: 85.9%). In patients who received placebo through Weeks\u200916\u201348, PASI 75 response decreased (Week\u200948: 60.4%), then increased following Week 48 switch to 200\u2009mg Q2W (Week 144: 95.1%). 48\u2009and 36 patients initially randomized to 200 and 400\u2009mg Q2W, respectively, were Week 16 PASI\u200975 non\u2010responders and entered the escape arm; at Week 144, 71.8% and 78.2% achieved PASI 75. No new safety signals were identified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Response to CZP was durable over three years; no new safety signals were identified.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.17486","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T08:55:35Z","timestamp":1625129735000},"page":"2398-2408","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Three\u2010year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial"],"prefix":"10.1111","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-6481","authenticated-orcid":false,"given":"R. B.","family":"Warren","sequence":"first","affiliation":[{"name":"Dermatology Centre Salford Royal NHS Foundation Trust Manchester NIHR Biomedical Research Centre The University of Manchester Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4705-5303","authenticated-orcid":false,"given":"M.","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7789-6915","authenticated-orcid":false,"given":"H.","family":"Sofen","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine at UCLA Los Angeles CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6079-4517","authenticated-orcid":false,"given":"V.","family":"Piguet","sequence":"additional","affiliation":[{"name":"Division of Dermatology Department of Medicine University of Toronto Toronto ON Canada"},{"name":"Division of Dermatology Department of Medicine Women\u2019s College Hospital Toronto ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-8728","authenticated-orcid":false,"given":"M.","family":"Augustin","sequence":"additional","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP) University Medical Center Hamburg\u2010Eppendorf (UKE) Hamburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Brock","sequence":"additional","affiliation":[{"name":"UCB Pharma Slough UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"C.\u2009Arendt","sequence":"additional","affiliation":[{"name":"UCB Pharma Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Fierens","sequence":"additional","affiliation":[{"name":"UCB Pharma Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2633-985X","authenticated-orcid":false,"given":"A.","family":"Blauvelt","sequence":"additional","affiliation":[{"name":"Oregon Medical Research Center Portland OR USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,8,17]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12230"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.11.013"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.09.022"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.11.1088"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60726-6"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S98893"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.08.008"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.095"},{"key":"e_1_2_8_10_1","unstructured":"NICE.NICE Pathways: Psoriasis overview. Available at:https:\/\/pathways.nice.org.uk\/pathways\/psoriasis[Accessed 26 November 2020]."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15665"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14454"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.208"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13343"},{"key":"e_1_2_8_16_1","unstructured":"FDA.Cimzia (Certolizumab Pegol) Prescribing Information. Available at:https:\/\/www.accessdata.FDA.gov\/drugsatfda_docs\/label\/2019\/125160s237lbl.pdf[Accessed 26 November 2020]."},{"key":"e_1_2_8_17_1","unstructured":"Compendium EM.Cimzia. Available at:https:\/\/www.medicines.org.uk\/emc\/medicine\/32367[Accessed 26 November 2020]."},{"key":"e_1_2_8_18_1","first-page":"535","article-title":"A new generation of high\u2010affinity humanized PEGylated Fab' fragment anti\u2010tumor necrosis factor\u2010[alpha] monoclonal antibodies","volume":"3","author":"Weir N","year":"2006","journal-title":"Therapy"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212196"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211384"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40508"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.04.013"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.04.012"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15258"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19314"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19393"},{"key":"e_1_2_8_27_1","doi-asserted-by":"crossref","first-page":"e000582","DOI":"10.1136\/rmdopen-2017-000582","article-title":"4\u2010year results from the RAPID\u2010PsA phase 3 randomised placebo\u2010controlled trial of certolizumab pegol in psoriatic arthritis","volume":"4","author":"Heijde D","year":"2018","journal-title":"RMD Open"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.826341"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203695"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex174"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12930"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.057"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.056"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.12.005"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67566-6"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.6.719"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.17486","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.17486","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.17486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T11:35:09Z","timestamp":1692963309000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.17486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,17]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1111\/jdv.17486"],"URL":"https:\/\/doi.org\/10.1111\/jdv.17486","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,17]]},"assertion":[{"value":"2021-02-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}